Heterogeneity of autoantibodies to factor VIII: differences in specificity for apparently distinct antigenic determinants of factor VIII coagulant protein.

نویسندگان

  • M P Croissant
  • M Zuzel
  • J P Allain
چکیده

The interference of antibodies to factor VIII coagulant protein (VIII:C) of 9 nonhemophilic patients with the binding to factor VIII coagulant antigen (VIII:CAg) of a reference hemophilic 125I-Fab' reagent, used in a liquid phase VIII:CAg assay, was studied. The binding competition was estimated from immunoradiometric assay (IRMA) dose-response slope of VIII:CAg present in patient plasma, interference of antibodies with the 125I-Fab' binding to VIII:CAg in normal plasma, and the displacement of antibody from the complexes with VIII:CAg by the 125I Fab'. Antibody populations from three patients were studied in detail; in the VIII:CAg assay, two of them interfered with the 125I-Fab' binding, and one did not (patient 1). The formation of stable complexes between antibodies of each patient and VIII:CAg was demonstrated by protein-A-Sepharose adsorption. The 125I-Fab' binding to VIII:CAg-anti-VIII:CAg IgG complexes indicated that patient 1 antibodies and the 125I-Fab' recognized different antigenic determinants, whereas the other two patient antibodies and 125I-Fab' recognized closely related or identical VIII:CAg determinants. These results demonstrate an apparently selective recognition of at least two distinct VIII:CAg determinants by naturally occurring antibodies, suggesting a possibility of a wider use of these antibodies in studies of the structure and function of factor VIII.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Heterogeneity of Autoantibodies to Factor VIII : Differences in Specificity for Apparently Distinct Antigenic Determinants of Factor

The interference of antibodies to factor VIII coagulant protein (Vlll:C) of 9 nonhemophilic patients with the binding to factor VIII coagulant antigen (VIII:CAg) of a reference hemophilic ‘251-Fab’ reagent, used in a liquid phase Vlll:CAg assay, was studied. The binding competition was estimated from immunoradiometric assay (IRMA) doseresponse slope of Vlll:CAg present in patient plasma. interf...

متن کامل

Combined Factor V and VIII Deficiency

This review summarizes current data on the pathomechanisms and new genetic findings of combined factor V and VIII deficiency (CF5F8D). Congenital haemorrhagic disorders characterized by deficiency of two clotting factors comprise an interesting group. Among dual coagulation disorders, CF5F8D is the most common type. For the first time combined factor V and VIII deficiency (F5F8D) was reported b...

متن کامل

Development of aptameric affinity ligands specific to human plasma coagulation factor VIII using SEC-SELEX

Protein specific aptamers are highly applicable affinity ligands in different fields of research and clinical applications. They have been developed against various targets, in particular, bio-macromolecules such as proteins. Among human proteins, the coagulation factors are the most attractive targets for aptamer selection and their specific aptamers had valuable characteristics in therapeutic...

متن کامل

Development of aptameric affinity ligands specific to human plasma coagulation factor VIII using SEC-SELEX

Protein specific aptamers are highly applicable affinity ligands in different fields of research and clinical applications. They have been developed against various targets, in particular, bio-macromolecules such as proteins. Among human proteins, the coagulation factors are the most attractive targets for aptamer selection and their specific aptamers had valuable characteristics in therapeutic...

متن کامل

THE ROLE OF VARIOUS STABILIZERS IN THE ACQUISITION OF THERMO-TOLER ANCE IN FACTOR VIII ACTIVITY

We prepared a highly purified and relatively heat stable form of factor VIII which contained 25 units per mL (u/mL) activity using PEG-4000 and developed an effective and new manufacturing process. Heat treatment was performed at 80°C for 72 hrs in the presence of different stabilizers. In our studies, we used different organic solvents as preservatives to maintain factor VIII activity, sin...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Blood

دوره 62 1  شماره 

صفحات  -

تاریخ انتشار 1983